pyrazines has been researched along with Adverse Drug Event in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (35.29) | 29.6817 |
| 2010's | 15 (44.12) | 24.3611 |
| 2020's | 7 (20.59) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelaal, AH; Abozaid, AA; Ads, AM; Alhijazeen, S; Aziz, JMA; Ghula, S; Hirayama, K; Hung, DT; Huy, NT; Ibrahim, AM; Iiyama, T; Karmally, Z; Kita, K; Kouz, B; Le, TN; Makram, AM; Nakhare, S; Nam, NH; Pancharatnam, RA; Phuong, NQ; Shabouk, MB; Tawfik, GM; Turnage, M | 1 |
| Lee, T; Mitomi, T; Sugamori, H; Yamagishi, C | 1 |
| de Lamballerie, X; Extramiana, F; Malvy, D; Mentre, F; Taburet, AM | 1 |
| Abe, S; Fujimori, D; Kaizuka, H; Otsuki, S; Takeuchi, Y; Takoi, H; Togashi, Y; Wada, T | 1 |
| Azuma, T; Furumoto, A; Haku, T; Hidaka, M; Himeji, D; Ikeda, K; Ishida, M; Ishimaru, T; Kadowaki, N; Kakihana, Y; Kamikokuryo, C; Kaneko, M; Kawamura, M; Kurosu, T; Ohge, H; Saijo, M; Sakabe, S; Shimojima, M; Suemori, K; Takahashi, T; Takenaka, K; Taniguchi, T; Yamanaka, A; Yasukawa, M; Yoshikawa, T | 1 |
| Baek, M; Brown, JR; Byrd, JC; Chernyukhin, N; Christian, B; Dyer, MJS; Furman, RR; Ghia, P; Hamdy, AM; Hillmen, P; Izumi, R; Jurczak, W; Lezhava, T; O'Brien, SM; Owen, RG; Pagel, JM; Patel, P; Rule, S; Sharman, JP; Stephens, DM; Streetly, MJ; Sun, C; Wang, M | 1 |
| Amani, B; Arab-Zozani, M; Fathalipour, M; Hassanipour, S; Heidarzad, F; Martinez-de-Hoyo, R | 1 |
| Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M | 1 |
| Akashi, K; Aoki, T; Ito, Y; Kamimura, T; Miyamoto, T; Yokota, N | 1 |
| Fu, W; Hou, J; Huang, H; Peng, L; Zhang, C; Zhou, L | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Ahn, JS; Ahn, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH | 1 |
| Colson, K | 1 |
| Inukai, M; Mio, M; Suzuki, T; Ueda, T; Yasuhara, N | 1 |
| Baudin, E; Berruti, A; Chen, J; Choueiri, TK; Demeure, MJ; Fassnacht, M; Fleege, T; Gilbert, J; Haak, H; Hammer, GD; Hesseltine, E; Kroiss, M; Poondru, S; Quinn, DI; Ronchi, CL; Rorig, R; Stephens, AW; Terzolo, M; Worden, F | 1 |
| Kolesar, J; Utecht, KN | 1 |
| Ohashi, K | 1 |
| Kao, DP | 1 |
| Bentz, M; Dreyling, M; Hiddemann, W; Jentsch-Ullrich, K; Mueck, R; Rohrberg, R; von Schilling, C; Weidmann, E; Weigert, O | 1 |
| Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E | 1 |
| Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E | 1 |
| Cheng, B; Cheung, YK; Lee, SM | 1 |
| Anderl, JL; Arastu-Kapur, S; Ball, AJ; Bennett, MK; Driessen, C; Kirk, CJ; Kraus, M; Lee, SJ; Muchamuel, T; Parlati, F; Shenk, KD | 1 |
| Cavalli, M; Chiarenza, A; Consoli, U; Conticello, C; Coppolino, F; Di Raimondo, F; Forte, S; Palumbo, GA; Romano, A; Uccello, G; Vetro, C | 1 |
| Mateos, MV | 1 |
| Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Jayabalan, DS; Lane, ME; Manco, M; Mark, TM; Mathews, L; Niesvizky, R; Pearse, RN; Pekle, K; Shore, TB; Skerret, D; Stern, J; Ward, M; Xiang, Z; Zafar, F | 1 |
| Hussar, DA | 1 |
| Colson, K; Jagannath, S; Richardson, P | 1 |
| Jagannath, S | 1 |
| Richardson, P | 1 |
| Farombi, EO; Surh, YJ | 1 |
| Lonial, S | 1 |
| Alegre, A; Bladé, J; de la Rubia, J; García-Sánchez, P; Gutiérrez, N; Herrero, C; Lahuerta, JJ; Liu, X; Mateos, MV; Oriol, A; Rosiñol, L; San Miguel, J; Sureda, A; Van de Velde, H | 1 |
| Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; San-Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
8 review(s) available for pyrazines and Adverse Drug Event
| Article | Year |
|---|---|
The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.
Topics: Amides; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hyperuricemia; Pyrazines; SARS-CoV-2; Treatment Outcome | 2022 |
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Topics: Amides; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Intensive Care Units; Pyrazines; SARS-CoV-2; Survival Analysis; Treatment Outcome; Viral Load | 2021 |
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Induction Chemotherapy; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrazines | 2008 |
[Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Transplantation; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Transplantation, Homologous | 2008 |
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Related Side Effects and Adverse Reactions; Humans; Kinetics; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Heme oxygenase-1 as a potential therapeutic target for hepatoprotection.
Topics: Anesthetics; Animals; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Garlic; Heme Oxygenase-1; Humans; Liver; Liver Diseases; Metals, Heavy; Pyrazines; Signal Transduction; Thiones; Thiophenes | 2006 |
8 trial(s) available for pyrazines and Adverse Drug Event
| Article | Year |
|---|---|
Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
Topics: Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Placebos; Protein Kinase Inhibitors; Pyrazines | 2015 |
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis | 2009 |
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Rituximab; Survival Analysis; Waldenstrom Macroglobulinemia | 2010 |
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome | 2010 |
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Filgrastim; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplastic Stem Cells; Pyrazines; Recombinant Proteins; Signal Transduction | 2013 |
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Linear Models; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Survival Analysis; Treatment Outcome | 2008 |
18 other study(ies) available for pyrazines and Adverse Drug Event
| Article | Year |
|---|---|
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.
Topics: Aniline Compounds; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Mutation; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Pyrazines | 2022 |
The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers.
Topics: Amides; Antiviral Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Heart Conduction System; Hemorrhagic Fevers, Viral; Humans; Pyrazines | 2020 |
Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
Topics: Adult; Amides; Antiviral Agents; Body Temperature; COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Fever; Humans; Male; Pyrazines; SARS-CoV-2; Treatment Outcome | 2020 |
A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome.
Topics: Adult; Aged; Aged, 80 and over; Amides; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Liver Diseases; Male; Middle Aged; Phlebovirus; Pyrazines; RNA, Viral; Severe Fever with Thrombocytopenia Syndrome; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Viral Load | 2021 |
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; United States | 2021 |
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Retrospective Studies; Skin; Thalidomide | 2014 |
High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors | 2013 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Reaction of acetaldehyde with 5-aminolevulinic acid via dihydropyrazine derivative.
Topics: Acetaldehyde; Aminolevulinic Acid; Animals; Chromatography, High Pressure Liquid; Dimerization; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Hydrogen-Ion Concentration; Lethal Dose 50; Male; Mass Spectrometry; Mice; Mice, Inbred ICR; Propionates; Pyrazines | 2015 |
What can we learn from drug marketing efficiency?
Topics: Adverse Drug Reaction Reporting Systems; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Marketing; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles | 2008 |
Continual reassessment method with multiple toxicity constraints.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine | 2011 |
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cells, Cultured; Cysteine Endopeptidases; Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; Hep G2 Cells; Humans; Male; Models, Biological; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley | 2011 |
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2013 |
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence | 2006 |
The safety and efficacy of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate; Treatment Outcome | 2006 |
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Thrombocytopenia; Treatment Outcome | 2006 |
Management of toxicities associated with bortezomib.
Topics: Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Treatment Outcome | 2006 |